The NDA acceptance and absence of an AdCom are modest positives that de-risk the regulatory path, but the PDUFA date is nearly 10 months out. Traders should monitor for any FDA review updates or clinical data releases ahead of May 2027. The stock's historical neutral filings have underperformed, so near-term upside may be limited until a clearer catalyst emerges.
Price Chart
Executive Summary
Axsome Therapeutics announced FDA acceptance of its NDA for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting, which reduces regulatory uncertainty. This is a procedural milestone for a mid-stage pipeline asset, not a revenue-generating event, and the stock's historical reaction to neutral filings has been negative on average.
Key Facts
- FDA accepted NDA filing for AXS-12 (reboxetine) to treat cataplexy in narcolepsy
- PDUFA target action date set for May 1, 2027
- FDA indicated no advisory committee meeting is currently planned
- AXS-12 has Orphan Drug Designation for narcolepsy
- Cataplexy affects an estimated 70% of narcolepsy patients
Financial Impact
No financial terms disclosed; AXS-12 is not yet approved and has no revenue. Orphan drug designation provides market exclusivity potential if approved.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) at the PDUFA date
- AXS-12 is not yet approved and has no commercial revenue
- Long timeline to PDUFA (May 2027) leaves room for negative developments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3327580 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $176.28 (−17.88%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.28 (−20.20%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.28 (−20.20%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $176.28 (−25.79%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $176.28 (−29.19%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $176.28 (−29.42%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $176.28 (−27.85%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $176.28 (−30.43%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.28 (−30.92%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.28 (−30.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access